Peony and Improved Overall Response Rate

Doses used in studies

Time to effect

Median: 12.2 months · IQR 12.2 months–12.2 months · Range 12.2 months–12.2 months — Reported in 1 of 2 studies

Safety in these studies

abdominal symptomsIncreased riskRR = 3.27, 95% CI = 1.62 to 6.60, p < 0.001
Moreover, TGP treatment was associated with a higher incidence of abdominal symptoms (RR = 3.27, 95% CI = 1.62 to 6.60, p < 0.001).
from: Efficacy and safety of total glucosides of paeony in the treatment of recurrent aphthous u
diarrheaIncreased risk5.5% vs. 0.9%
The safety analysis primarily showed mild adverse events, with a higher incidence of diarrhea in the TGP group (5.5% vs. 0.9%)
from: Clinical effectiveness and safety of total glucosides of paeony as an immunomodulator in p
adverse events (mild)Reported
The safety analysis primarily showed mild adverse events, with a higher incidence of diarrhea in the TGP group (5.5% vs. 0.9%), but no severe events or treatment discontinuations.
from: Clinical effectiveness and safety of total glucosides of paeony as an immunomodulator in p
severe adverse eventsReportedSerious adverse event
but no severe events or treatment discontinuations.
from: Clinical effectiveness and safety of total glucosides of paeony as an immunomodulator in p

2 of 2 papers

Efficacy and safety of total glucosides of paeony in the treatment of recurrent aphthous ulcers: a systematic review and meta-analysis.